About: Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection
Creator	Judson, Gregory Benjamin, W Joyce, N Kelemen, Mahadevan, Njoroge, Vaikom, S
Source	Medline; PMC
abstract	The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has profoundly impacted all fields of medicine. Infection with SARS-CoV-2 and the resulting coronavirus of 2019 (COVID-19) syndrome has multiorgan effects. The pandemic has united researchers from bench to bedside in attempts to understand the pathophysiology of the disease and define optimal treatment strategies. Cardiovascular disease is highly prevalent and a leading cause of death across gender, race, and ethnic groups. As the pandemic spreads, there is increasing concern about the cardiovascular effects of the viral infection and the interaction of infection with existing cardiovascular disease. Additionally, there are concerns about the cardiac effects of the numerous treatment agents under study. It will be essential for cardiologists to understand the interplay between underlying cardiac comorbidities, acute cardiovascular effects of COVID-19 disease, and adverse effects of new treatments. Here we describe emerging evidence of the epidemiology of SARS-CoV-2 infection and underlying cardiovascular disease, the evidence for direct myocardial injury in SARS-CoV-2 infection, the specific presentations of cardiovascular involvement by SARS-CoV-2, and the cardiac effects of emerging treatments.
has issue date	2020-06-13(xsd:dateTime)
bibo:doi	10.1007/s40119-020-00184-5
bibo:pmid	32535752
has license	no-cc
sha1sum (hex)	bb16742bf320d4f199b22e31bd6cdffef426cc2f
schema:url	https://doi.org/10.1007/s40119-020-00184-5
resource representing a document's title	Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection
has PubMed Central identifier	PMC7292941
has PubMed identifier	32535752
schema:publication	Cardiol Ther
resource representing a document's body	covid:bb16742bf320d4f199b22e31bd6cdffef426cc2f#body_text
is schema:about of	named entity 'pandemic' named entity 'prevalent' named entity 'disease' named entity 'effects' named entity 'cardiovascular disease' named entity 'strategies' named entity 'ongoing' named entity 'COVID-19' named entity 'MEDICINE' named entity 'CARDIOVASCULAR' named entity 'interplay' named entity 'gender' named entity 'cardiac' named entity 'leading' named entity 'presentations' named entity 'adverse effects' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'COVID' named entity 'viral infection' named entity 'SARS-CoV-2' named entity 'cardiac effects' named entity 'infection' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'infection' named entity 'COVID' named entity 'cardiovascular' named entity 'pandemic' named entity 'cardiovascular' named entity 'SARS-CoV-2' named entity 'heterogeneity' named entity 'left ventricular ejection fraction' named entity 'COVID-19' named entity 'Wuhan' named entity 'thrombolytics' named entity 'myocarditis' named entity 'ACE2 receptor' named entity 'SARS-CoV-2' named entity 'anticoagulation' named entity 'tobacco' named entity 'cardiac failure' named entity 'myocarditis' named entity 'cardiac dysfunction' named entity 'COVID' named entity 'thromboses' named entity 'case series' named entity 'biomarkers' named entity 'venous thromboembolism' named entity 'viral entry' named entity 'cardiovascular' named entity 'infection' named entity 'viruses' named entity 'troponin' named entity 'critical illness' named entity 'stark reality' named entity 'IVIG' named entity 'heart failure' named entity 'WHO' named entity 'diabetes' named entity 'protein' named entity 'Creative Commons' named entity 'infection' named entity 'SARS-CoV-2' named entity 'respiratory support' named entity 'United States' named entity 'mechanical ventilation' named entity 'COVID-19' named entity 'D-dimer' named entity 'respiratory failure' named entity 'Louisiana' named entity 'COVID' named entity 'critically ill patients' named entity 'protease'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software